444 related articles for article (PubMed ID: 19546801)
1. Venous thromboembolism in lymphoma: how effectively are we treating patients?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA
Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801
[TBL] [Abstract][Full Text] [Related]
2. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of a pharmacist-managed anticoagulation service for breast cancer patients.
Jones KL; Barnett C; Gauthier M; Boster B; Espirito JL; Michaud LB
J Oncol Pharm Pract; 2012 Mar; 18(1):122-7. PubMed ID: 21364079
[TBL] [Abstract][Full Text] [Related]
4. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
5. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Thachil J
Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
[TBL] [Abstract][Full Text] [Related]
6. Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures.
Clark NP; Witt DM; Davies LE; Saito EM; McCool KH; Douketis JD; Metz KR; Delate T
JAMA Intern Med; 2015 Jul; 175(7):1163-8. PubMed ID: 26010033
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Schulman S; Kakkar AK; Goldhaber SZ; Schellong S; Eriksson H; Mismetti P; Christiansen AV; Friedman J; Le Maulf F; Peter N; Kearon C;
Circulation; 2014 Feb; 129(7):764-72. PubMed ID: 24344086
[TBL] [Abstract][Full Text] [Related]
8. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
9. Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center.
Labrador J; González-Rivero J; Monroy R; Lozano FS; López-Corral L; Caballero MD; Bastida JM; González-Porras JR
Thromb Res; 2016 Jun; 142():52-6. PubMed ID: 26922092
[TBL] [Abstract][Full Text] [Related]
10. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
11. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis.
Ihaddadene R; Le Gal G; Delluc A; Carrier M
Thromb Res; 2014 Jul; 134(1):93-5. PubMed ID: 24835673
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
14. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.
Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC
Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480
[TBL] [Abstract][Full Text] [Related]
15. [The study of Chinese optimal anticoagulant range of warfarin for venous thromboembolism].
Yang P; Wu QH; Luo XY; Kou L; Chen Z; Zhang YY; Zhou H
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(25):1762-5. PubMed ID: 19862981
[TBL] [Abstract][Full Text] [Related]
16. Periprocedural anticoagulation management of patients with venous thromboembolism.
McBane RD; Wysokinski WE; Daniels PR; Litin SC; Slusser J; Hodge DO; Dowling NF; Heit JA
Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):442-8. PubMed ID: 20139361
[TBL] [Abstract][Full Text] [Related]
17. Treatment of venous thromboembolism in cancer patients.
Petralia GA; Kakkar AK
Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
Douketis JD; Johnson JA; Turpie AG
Arch Intern Med; 2004 Jun; 164(12):1319-26. PubMed ID: 15226166
[TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
Soto-Cárdenas MJ; Pelayo-García G; Rodríguez-Camacho A; Segura-Fernández E; Mogollo-Galván A; Giron-Gonzalez JA
Palliat Med; 2008 Dec; 22(8):965-8. PubMed ID: 18952751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]